Cargando…

Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?

Obesity is a chronically progressing disease that represents a major challenge for affected patients, health care professionals and society, since it is highly prevalent and associated with several comorbidities. The treatment of obesity aims at body weight reduction, reducing the burden of comorbid...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Timo D., Blüher, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246874/
https://www.ncbi.nlm.nih.gov/pubmed/37286802
http://dx.doi.org/10.1007/s00108-023-01530-0
_version_ 1785055122042126336
author Müller, Timo D.
Blüher, Matthias
author_facet Müller, Timo D.
Blüher, Matthias
author_sort Müller, Timo D.
collection PubMed
description Obesity is a chronically progressing disease that represents a major challenge for affected patients, health care professionals and society, since it is highly prevalent and associated with several comorbidities. The treatment of obesity aims at body weight reduction, reducing the burden of comorbidities and weight maintenance after weight loss. To achieve these goals, a conservative treatment strategy is recommended that consists of an energy-reduced diet, increased physical activity and behavioral modifications. If individual treatment targets cannot be achieved by basic treatment, stepwise therapy intensification should be initiated including short-term very low calorie diets, pharmacotherapy or bariatric surgery. However, these treatment approaches differ with respect to average weight loss and other outcomes. There is still a large gap between the efficacy of conservative strategies and “metabolic” surgery that cannot be filled by current pharmacotherapies. However, recent advances in the development of anti-obesity medications could change the positioning of pharmacotherapies in obesity management. Here we discuss whether next-generation pharmacotherapies have the potential to become an alternative to obesity surgery in the future.
format Online
Article
Text
id pubmed-10246874
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-102468742023-06-08 Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein? Müller, Timo D. Blüher, Matthias Inn Med (Heidelb) Schwerpunkt: Fettstoffwechsel und Metabolisches Syndrom Obesity is a chronically progressing disease that represents a major challenge for affected patients, health care professionals and society, since it is highly prevalent and associated with several comorbidities. The treatment of obesity aims at body weight reduction, reducing the burden of comorbidities and weight maintenance after weight loss. To achieve these goals, a conservative treatment strategy is recommended that consists of an energy-reduced diet, increased physical activity and behavioral modifications. If individual treatment targets cannot be achieved by basic treatment, stepwise therapy intensification should be initiated including short-term very low calorie diets, pharmacotherapy or bariatric surgery. However, these treatment approaches differ with respect to average weight loss and other outcomes. There is still a large gap between the efficacy of conservative strategies and “metabolic” surgery that cannot be filled by current pharmacotherapies. However, recent advances in the development of anti-obesity medications could change the positioning of pharmacotherapies in obesity management. Here we discuss whether next-generation pharmacotherapies have the potential to become an alternative to obesity surgery in the future. Springer Medizin 2023-06-07 /pmc/articles/PMC10246874/ /pubmed/37286802 http://dx.doi.org/10.1007/s00108-023-01530-0 Text en © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Schwerpunkt: Fettstoffwechsel und Metabolisches Syndrom
Müller, Timo D.
Blüher, Matthias
Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
title Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
title_full Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
title_fullStr Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
title_full_unstemmed Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
title_short Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
title_sort adipositastherapie – werden pharmakotherapien die alternative zur metabolischen chirurgie sein?
topic Schwerpunkt: Fettstoffwechsel und Metabolisches Syndrom
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246874/
https://www.ncbi.nlm.nih.gov/pubmed/37286802
http://dx.doi.org/10.1007/s00108-023-01530-0
work_keys_str_mv AT mullertimod adipositastherapiewerdenpharmakotherapiendiealternativezurmetabolischenchirurgiesein
AT bluhermatthias adipositastherapiewerdenpharmakotherapiendiealternativezurmetabolischenchirurgiesein